Colon Cancer

In early CRC, higher disease activity and specific changes, such as increased DAI scores and reduced serum estradiol in females than in males. BC supplementation could effectively reduce DAI scores and systemic inflammation in both sexes. Notably, serum cytokine levels decreased only in females.

Furthermore, FBXW7 alterations contribute to chemoresistance and anti-EGFR therapy resistance but also reveal potential therapeutic vulnerabilities. These findings underscore FBXW7's promise as a prognostic biomarker and a potential target for precision oncology strategies in colorectal cancer.

The use of prolgolimab in locally advanced dMMR/MSI CRC is associated with high rates of pCR and cCR, allowing for further exploration of organ-sparing approaches in these patients.

Intrinsic S701 underwent reversible phosphorylation catalyzed by mechanistic target of rapamycin complex 1 (mTORC1) and protein phosphatase 2A (PP2A)...Pharmacological inhibition of PP2A sustained p-S701 and alleviated colon inflammation in wild-type but not in ΔS701 mice. Our findings highlight the importance of STAT3 heterogeneity in colonic inflammation and colorectal cancer.

We revealed the key biological mechanisms involved in the invasion and colonization phases of iCCA liver metastasis. Moreover, we provide valuable data for understanding iCCA liver metastasis and a possible avenue for the treatment of advanced iCCA.

This highlights the significance of multidisciplinary management, incorporating immunotherapy, surgical interventions, and vascular assessment to optimize clinical outcomes in dMMR colorectal cancer complicated by vascular pathologies such as SAM. Further investigation into the relationship between vascular pathologies, such as SAM, and malignancy is warranted.

LUNA is the first randomized study to evaluate the potential benefit of hepatectomy for patients with colorectal cancer with resectable liver and unresectable low-volume lung metastases. The trial was closed early and did not meet the primary endpoint. Findings from the as-treated analysis may warrant validation in a larger, multicenter cohort.

P=N/A, N=33, Completed, Radboud University Medical Center | Active, not recruiting --> Completed | N=60 --> 33 | Trial primary completion date: Sep 2025 --> May 2025

P2/3, N=100, Recruiting, Turku University Hospital

P2, N=25, Active, not recruiting, The Netherlands Cancer Institute | Trial completion date: Nov 2026 --> Jul 2031 | Trial primary completion date: Nov 2025 --> Jul 2030

Histopathological evaluation may aid risk stratification alongside KRAS status. Prognostic assessment in clinical settings should take both TNM staging and KRAS status into account.

P1, N=135, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting